Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on June 6, 2025
Rectify Pharma Presents Translational Data Demonstrating Improvements in Kidney Function and Reductions in Vascular Calcification at ERA 2025
GlobeNewswire
·
June 6, 2025
Potent, selective ABCC6-targeting positive functional modulator (PFM) improved multiple markers of renal function in animal models of chronic kidney disease (CKD) PFM improved inorganic pyrophosphate (PPi) efflux via on-target engagement of the ABCC6 …
Polpharma Group soutient l’action urgente de l’UE visant à garantir l’accès aux médicaments et à renforcer la souveraineté pharmaceutique européenne
GlobeNewswire
·
June 6, 2025
AMSTERDAM, 06 juin 2025 (GLOBE NEWSWIRE) -- Polpharma Group, fabricant européen de produits pharmaceutiques de premier plan, s’est joint aux autres membres de l’association Medicines for Europe pour signer une lettre ouverte adressée aux Premiers ministres …
Die Polpharma Group unterstützt dringende Maßnahmen der EU zur Sicherung des Zugangs zu Arzneimitteln und zur Stärkung der pharmazeutischen Souveränität Europas
GlobeNewswire
·
June 6, 2025
AMSTERDAM, June 06, 2025 (GLOBE NEWSWIRE) -- Die Polpharma Group, ein führender europäischer Pharmahersteller, hat sich anderen Mitgliedern von Medicines for Europe angeschlossen und einen offenen Brief an die Premierminister und Gesundheitsminister aller …
Burning Rock Reports First Quarter 2025 Financial Results
GlobeNewswire
·
June 6, 2025
GUANGZHOU, China, June 06, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today …
浩鼎自創ADC平台GlycOBI® 首宗技術合作案 攜手美國TegMine開發ADC
GlobeNewswire
·
June 6, 2025
台灣, June 06, 2025 (GLOBE NEWSWIRE) -- 浩鼎生技（以下簡稱「浩鼎」）（4174.TWO）今（06/06）宣布，與美國TegMine Therapeutics, Inc.（以下簡稱「TegMine」）簽署ADC研發服務合約（Master Services Agreement, MSA）；TegMine 是一家總部位於美國舊金山的生物製藥公司，專注於開發針對癌症相關醣蛋白的創新抗體療法。浩鼎則致力於開發抗癌新藥及聚焦研發次世代抗體藥物複合體（ADCs）。 根據合約，浩鼎將與 …
OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies
GlobeNewswire
·
June 6, 2025
TAIPEI, Taiwan, June 06, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugates (ADCs) (4174. TWO), and TegMine Therapeutics, Inc. …